Blog: THERMOGENESIS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01. Regulation FD Disclosure

On January 10, 2022, ThermoGenesis Holdings, Inc., (the “Company”) provided an
update to its corporate presentation. The presentation will be available on the
Company’s website at and filed herewith as Exhibit 99.1.

The information set forth in this Item 7.01, including Exhibit 99.1, is being
furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section, and it shall not
be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or under the Exchange Act, whether made before or after the
date hereof, except as expressly provided by specific reference in such a

By filing this Current Report on Form 8-K and furnishing the information in this
Item 7.01, the Company makes no admission as to the materiality of Item 7.01 in
this report or the presentation attached hereto as Exhibit 99.1. The information
contained in the presentation is summary information that is intended to be
considered in the context of the Company’s filings with the SEC and other public
announcements that the Company makes, by press release or otherwise, from time
to time. The Company undertakes no duty or obligation to publicly update or
revise the information contained in this Item, although it may do so from time
to time as its management believes is appropriate. Any such updating may be made
through the filing of other reports or documents with the SEC, through press
releases or through other public disclosure.

The Company cautions you that the presentation attached hereto as Exhibit 99.1
contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act, as amended. Statements in the presentation that are not
purely historical are forward-looking statements including, but not limited to,
the Company’s ability to execute its business plan, obtain regulatory approval
for products under development, enter into partnering agreements, realize
revenue and pursue growth opportunities, some of which are outside the control
of the Company. Readers and attendees are cautioned not to place undue reliance
on these forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Attendees are urged to
read the risk factors set forth in the Company’s most recent annual report on
Form 10-K, subsequent quarterly reports filed on Form 10-Q and its most recent
SEC filings. Company disclaims any intention to update this presentation.


Item 9.01. Financial Statements and Exhibits.

(d)     Exhibits

Exhibit                                Description
99.1       Corporate Presentation, dated January 10, 2022, H.C. Wainwright
         BioConnect Conference (2022)
104      Cover Page Interactive Data File (embedded within the Inline XBRL


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s